Literature DB >> 12781069

Immunity against soft-tissue sarcomas.

Robert G Maki1.   

Abstract

Recent advances in basic medical sciences have led to a deeper understanding of the molecular characteristics of soft-tissue sarcomas. Likewise, novel technologies have led to a better appreciation of the relationship between an antigenic stimulus and the subsequent immune response against the antigen. In the past few years, the intersection of the understanding of the immune system and the knowledge of sarcoma biology has become apparent. As seen with other forms of cancer, there is a detectable autologous immune response against sarcomas. It is the hope of many investigators that the hints of a tumor-specific immune response will be enough to generate a signal that can be amplified and directed against the host sarcoma. The data regarding the initial evidence of immune responses against sarcomas are reviewed in the context of current or potential clinical studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781069     DOI: 10.1007/s11912-003-0067-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  37 in total

Review 1.  Wanted: a molecular basis for specificity in toll-like receptor signal transduction.

Authors:  Luke A J O'Neill
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

Review 2.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

3.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Authors:  Valérie Dutoit; Robert N Taub; Kyriakos P Papadopoulos; Susan Talbot; Mary-Louise Keohan; Michelle Brehm; Sacha Gnjatic; Paul E Harris; Brygida Bisikirska; Philippe Guillaume; Jean-Charles Cerottini; Charles S Hesdorffer; Lloyd J Old; Danila Valmori
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

4.  Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.

Authors:  John Wilkinson; Alethea Cope; Jas Gill; Dimitra Bourboulia; Peter Hayes; Nesrina Imami; Toru Kubo; Anne Marcelin; Vincent Calvez; Robin Weiss; Brian Gazzard; Chris Boshoff; Frances Gotch
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas.

Authors:  H R Chang; C Cordon-Cardo; A N Houghton; N K Cheung; M F Brennan
Journal:  Cancer       Date:  1992-08-01       Impact factor: 6.860

6.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

8.  Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.

Authors:  Jasjit Gill; Dimitra Bourboulia; John Wilkinson; Peter Hayes; Alethea Cope; Anne-Genevieve Marcelin; Vincent Calvez; Frances Gotch; Christopher Boshoff; Brian Gazzard
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-01       Impact factor: 3.731

9.  The desmoid tumor. IV. Choice of treatment, results, and complications.

Authors:  J J Reitamo
Journal:  Arch Surg       Date:  1983-11

10.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

View more
  3 in total

Review 1.  Potential for immunotherapy in soft tissue sarcoma.

Authors:  William W Tseng; Neeta Somaiah; Edgar G Engleman
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

Review 3.  Immunotherapies in sarcoma: Updates and future perspectives.

Authors:  Marwan Ghosn; Elie El Rassy; Hampig Raphael Kourie
Journal:  World J Clin Oncol       Date:  2017-04-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.